Lyell Immunopharma (LYEL) Operating Expenses: 2020-2025
Historic Operating Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $37.3 million.
- Lyell Immunopharma's Operating Expenses fell 26.26% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $342.9 million, marking a year-over-year increase of 57.91%. This contributed to the annual value of $358.8 million for FY2024, which is 45.19% up from last year.
- Latest data reveals that Lyell Immunopharma reported Operating Expenses of $37.3 million as of Q3 2025, which was down 20.96% from $47.1 million recorded in Q2 2025.
- Lyell Immunopharma's Operating Expenses' 5-year high stood at $201.2 million during Q4 2024, with a 5-year trough of $37.3 million in Q3 2025.
- Moreover, its 3-year median value for Operating Expenses was $57.4 million (2025), whereas its average is $68.0 million.
- In the last 5 years, Lyell Immunopharma's Operating Expenses surged by 237.96% in 2024 and then dropped by 26.26% in 2025.
- Over the past 5 years, Lyell Immunopharma's Operating Expenses (Quarterly) stood at $50.4 million in 2021, then climbed by 25.44% to $63.2 million in 2022, then declined by 5.78% to $59.5 million in 2023, then spiked by 237.96% to $201.2 million in 2024, then declined by 26.26% to $37.3 million in 2025.
- Its last three reported values are $37.3 million in Q3 2025, $47.1 million for Q2 2025, and $57.4 million during Q1 2025.